Results 181 to 190 of about 22,611 (308)

Regression methods for cost-effectiveness analysis with different censoring times or terminating events for survival time and costs. [PDF]

Biometrics
Liu D, Chen S.
europepmc   +1 more source

Impact of Smoking on Treatment Outcomes in Patients With Human Papillomavirus‐Related Oropharyngeal Cancer

Head &Neck, EarlyView.
ABSTRACT Background Patients with HPV+ oropharyngeal cancer (OPC) have worse outcomes with longer smoking history (≥ 10 pack‐years). This has been confirmed in trials of primary radiotherapy but not surgery, suggesting differential smoking impact by treatment received. We assessed smoking‐related outcomes at a single institution.
Michelle M. Kwan, Latifa A. Bazzi, Zequn Sun, Dayton Rand, Asher Park, Shravan Asthana, Alexis Larson, Poonam Yadav, Bharat B. Mittal, Adil Akthar, Sarah Kramer, Jochen H. Lorch, Sandeep Samant, Urjeet Patel, Michelle L. Mierzwa, Leila J. Mady, Katelyn O. Stepan, Laila A. Gharzai   +17 more
wiley   +1 more source

Proportional Hazards Regression for Interval-Censored Outcomes With an Interval-Censored Covariate. [PDF]

Stat Med
Li D, Song Y, Lu W, Günthard HF, Kouyos R, Wang R.   +5 more
europepmc   +1 more source

Aspects of competing risks survival analysis [PDF]

This thesis is focused on the topic of competing risks survival analysis. The first chapter provides an introduction and motivation with a brief literature review.
Bond, Simon James
core  

Systemic Treatments for Recurrent or Metastatic Sinonasal Carcinomas: A Retrospective Multicenter Study

Head &Neck, EarlyView.
ABSTRACT Introduction Sinonasal cancers are rare and heterogeneous and pose a therapeutic challenge at an advanced stage due to the lack of data on appropriate systemic management. Methods This retrospective multicenter study analyzed 83 patients with recurrent or metastatic sinonasal carcinomas ineligible for curative treatment, treated in France ...
Marie Degrange, Mathilde Morisseau, Justin Michel, Thibaut Reverdy, Sylvain Morinière, Amaury Daste, Maxime Humbert, Caroline Viala, Pauline Corbaux, Tiffany Darbas, François‐Régis Ferrand, Valentin Favier, Camille Evrard, Diane Evrard, Delphine Farneti, Sarah Betrian‐Lagarde, Victor Sarradin   +16 more
wiley   +1 more source

Small Area Estimation of Education Levels in Low- and Middle-Income Countries. [PDF]

Ann Appl Stat
Wu Y, Dharamshi A, Wakefield J.
europepmc   +1 more source

Variations in Treatment Prescription and Survival Outcomes Between Older and Younger Patients With Mucosal Head and Neck Squamous Cell Carcinoma Treated With Radiotherapy

Head &Neck, EarlyView.
ABSTRACT Purpose To investigate treatment variations and outcomes between older (≥ 70 years) and younger (< 70 years) patients with mucosal head and neck squamous cell carcinoma (mHNSCC) treated with radiotherapy. Methods A multicenter retrospective review of patients diagnosed from 2010 to 2018 was conducted.
Farhannah Aly, Joseph Descallar, Purnima Sundaresan, Alexis Andrew Miller, Lois Holloway, Shalini Vinod   +5 more
wiley   +1 more source

SEMIPARAMETRIC ANALYSIS OF INTERVAL-CENSORED DATA SUBJECT TO INACCURATE DIAGNOSES WITH A TERMINAL EVENT. [PDF]

Ann Appl Stat
Deng Y, Zeng D, Wang Y.
europepmc   +1 more source

Randomized Phase II Trial of Consolidation Pembrolizumab After Definitive Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma: KCSG HN19‐09, CONPELAN Study

Head &Neck, EarlyView.
ABSTRACT Background The benefit of consolidation programmed cell death protein 1 (PD‐1) blockade after chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma (NPC) remains unclear. Methods Patients with stages II–IVB NPC were randomized (2:1) to pembrolizumab 200 mg or placebo every 3 weeks for up to 17 cycles after chemoradiotherapy ...
Sang Hoon Chun, Seyoung Seo, Jang Ho Cho, Keon‐Uk Park, Sang‐Cheol Lee, Yong Won Choi, Tak Yun, Seong Hoon Shin, Sung‐Bae Kim, Seungeun Lee, Chang Ho Ahn, Bhumsuk Keam   +11 more
wiley   +1 more source

Comparing adaptive treatment strategies in two-stage randomized trials with grouped survival data. [PDF]

Lifetime Data Anal
Sparkman M, Halabi S, Li Z.
europepmc   +1 more source